CGON Stock Summary and Trading Ideas (CG Oncology | NASDAQ:CGON)

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

CG Oncology trades on the NASDAQ stock market under the symbol CGON.

As of June 23, 2026, CGON stock price declined to $66.11 with 362,998 million shares trading.

CGON has a beta of 0.88, meaning it tends to be less sensitive to market movements. CGON has a correlation of 0.05 to the broad based SPY ETF.

CGON has a market cap of $5.83 billion. This is considered a Mid Cap stock.

Last quarter CG Oncology reported $1 million in Revenue and -$.71 earnings per share. This beat revenue expectation by $570,368 and missed earnings estimates by -$.16.

The top ETF exchange traded funds that CGON belongs to (by Net Assets): VTI, XBI, VB, IWM, VBR.

CGON has outperformed the market in the last year with a price return of +158.7% while the SPY ETF gained +24.7%. However, in the short term, CGON had mixed performance relative to the market. It has underperformed in the last 3 months, returning +1.6% vs +13.4% return in SPY. But in the last 2 weeks, CGON shares have fared better than the market returning +21.5% compared to SPY -0.5%.

CGON support price is $63.87 and resistance is $68.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGON shares will trade within this expected range on the day.